Posts tagged purinergic receptors
Can-Fite CEO to chair cancer conference session

Dr. Pnina Fishman, CEO of Can-Fite BioPharma (NYSE MKT:CANF; TASE:CFBI) will chair the plenary session titled, “Drugs Targeting Adenosine Receptors,” at the 2016 Keystone Symposia J5 in Vancouver, Canada on Jan. 24-28.

This year’s Purinergic Signaling symposium is a joint session with Keystone Symposia J6 Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies. The conference will focus on the leading developments in purinergic receptors, including the A3 adenosine receptor (A3AR) in the treatment of cancer.

Read More